Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,042,785
  • Shares Outstanding, K 272,708
  • Annual Sales, $ 2,169 M
  • Annual Income, $ 521,270 K
  • EBIT $ 762 M
  • EBITDA $ 791 M
  • 60-Month Beta 0.28
  • Price/Sales 5.80
  • Price/Cash Flow 23.96
  • Price/Book 5.97

Options Overview Details

View History
  • Implied Volatility 38.46% ( -3.10%)
  • Historical Volatility 38.14%
  • IV Percentile 46%
  • IV Rank 37.09%
  • IV High 72.42% on 08/05/24
  • IV Low 18.44% on 11/08/24
  • Put/Call Vol Ratio 0.19
  • Today's Volume 857
  • Volume Avg (30-Day) 2,436
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 50,488
  • Open Int (30-Day) 47,505

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.56
  • Number of Estimates 9
  • High Estimate 0.67
  • Low Estimate 0.51
  • Prior Year 0.75
  • Growth Rate Est. (year over year) -25.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.85 +9.18%
on 06/20/25
49.62 -12.31%
on 06/23/25
+0.48 (+1.12%)
since 06/06/25
3-Month
32.38 +34.37%
on 04/09/25
49.62 -12.31%
on 06/23/25
+9.38 (+27.48%)
since 04/08/25
52-Week
21.86 +99.04%
on 07/09/24
49.62 -12.31%
on 06/23/25
+21.42 (+96.97%)
since 07/08/24

Most Recent Stories

More News
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

/CNW/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation....

ONCY : 1.2500 (+23.76%)
CELC : 13.40 (+0.45%)
EXEL : 43.51 (-1.47%)
CTOR : 4.26 (-9.55%)
ONC.TO : 1.70 (+24.09%)
TOI : 2.50 (-2.34%)
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?

Exelixis EXEL has put up a stellar performance so far this year. Shares of the biotech company have rallied 35.2% in the past three months compared with the industry’s growth of 11.8%. The stock has...

MRK : 81.37 (+0.58%)
EXEL : 43.51 (-1.47%)
BMY : 47.04 (+1.18%)
2 Stocks to Buy With Less Than $50

EXEL : 43.51 (-1.47%)
PFE : 25.62 (+1.51%)
What's Fueling Tempus AI's Explosive Sales Growth?

Chicago-based Tempus AI, Inc. TEM is experiencing robust revenue growth, marked by record-setting financial performance. In the first quarter of 2025, the company reported a 75.4% year-over-year increase...

AZN : 70.02 (+0.56%)
EXAS : 53.54 (+2.02%)
EXEL : 43.51 (-1.47%)
TEM : 58.51 (+0.86%)
3 No-Brainer Stocks to Buy for Under $100 Right Now

AZN : 70.02 (+0.56%)
$SPX : 6,225.52 (-0.07%)
EXEL : 43.51 (-1.47%)
PFE : 25.62 (+1.51%)
The Zacks Analyst Blog Highlights Sprouts Farmers Market, Royal Gold, Thomson Reuters, Woodward and Exelixis

For Immediate ReleaseChicago, IL – June 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

WWD : 249.85 (-1.44%)
TRI : 200.33 (-0.40%)
EXEL : 43.51 (-1.47%)
RGLD : 160.23 (-4.76%)
SFM : 158.88 (-3.23%)
New Wave of Cancer Treatments Could Change the Game for Patients - and Investors

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The rising burden of cancer is poised to strain both healthcare systems and patient finances, especially...

ONCY : 1.2500 (+23.76%)
NRIX : 12.21 (-1.21%)
ORIC : 10.43 (-2.07%)
EXEL : 43.51 (-1.47%)
YMAB : 4.21 (-0.24%)
ONC.TO : 1.70 (+24.09%)
EXEL Stock Rises on Positive Data From Colorectal Cancer Study

Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the late-stage STELLAR-303 study.This phase III study is a global, multicenter, randomized,...

MRK : 81.37 (+0.58%)
EXEL : 43.51 (-1.47%)
BMY : 47.04 (+1.18%)
Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2

U.S. stock markets have suffered a setback in 2025 after the artificial intelligence (AI)-driven astonishing bull run of 2023 and 2024. The tech-heavy Nasdaq Composite witnessed an astonishing rally of...

WWD : 249.85 (-1.44%)
TRI : 200.33 (-0.40%)
EXEL : 43.51 (-1.47%)
RGLD : 160.23 (-4.76%)
SFM : 158.88 (-3.23%)
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

Incyte has underperformed relative to its biotech peers over the past year, though Wall Street analysts maintain a cautiously optimistic view on the stock’s outlook.

INCY : 67.67 (+0.59%)
EXEL : 43.51 (-1.47%)
XBI : 84.71 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 44.95
2nd Resistance Point 44.65
1st Resistance Point 44.08
Last Price 43.51
1st Support Level 43.21
2nd Support Level 42.91
3rd Support Level 42.34

See More

52-Week High 49.62
Last Price 43.51
Fibonacci 61.8% 39.02
Fibonacci 50% 35.74
Fibonacci 38.2% 32.46
52-Week Low 21.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar